GlassScriptPhysician profile
Roby A Thomas
NPI 1912266735
$4,892.75
in general payments reported to CMS, 2019-2025
16 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,897 · 2020: $1,744 · 2021: $263 · 2022: $742 · 2023: $31.11 · 2024: $107 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $179 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $178.95 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $1,932.20 | 2019-2020 | |
| Advanced Accelerator Applications | $1,485.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $590.08 | 2019-2025 | Imfinzi |
| Heron Therapeutics, INC. | $227.06 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $212.54 | 2020-2022 | |
| Beigene USA, INC. | $117.92 | 2022 | |
| Gilead Sciences, INC. | $111.26 | 2022 | |
| Celgene Corporation | $81.66 | 2022-2025 | Pomalyst, Opdivo |
| Tempus Ai, INC | $35.94 | 2024 | |
| Telix Pharmaceuticals | $32.67 | 2024 | Illuccix |
| Caris Mpi, INC. | $27.71 | 2025 | Mi Cancer Seek |
| Varian Medical Systems, INC. | $20.05 | 2019 | |
| Cardinal Health 414 LLC | $18.66 | 2024 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roby Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.